argenx Schedules Annual General Meeting of Shareholders for May 27, 2025

Argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Gent, Belgium, April 23, 2025 – Argenx SE (ARGX), a clinical-stage biotechnology company developing a pipeline of novel therapies for severe autoimmune diseases and cancer, today announced that its Annual General Meeting of shareholders will be held on May 27, 2025.

The meeting will take place at the company's headquarters located at Galgenwaard 4, 6812 AR, Arnhem, The Netherlands. The meeting will begin at 10:00 am CET.

The agenda for the meeting includes the election of directors, the ratification of the appointment of PricewaterhouseCoopers Accountants N.V. as the company's independent auditor, and the consideration of any other business that may properly come before the meeting.

The record date for the meeting is April 22, 2025, and shareholders of record as of this date will be entitled to vote at the meeting.

For further information regarding the meeting, shareholders may contact Argenx's secretary, Christelle Prévost, at c.prevost@argenx.com or +32 9 264 68 16.

About Argenx Argenx is a clinical-stage biotechnology company developing a pipeline of novel therapies for severe autoimmune diseases and cancer. The company's lead product candidate, ARGX-113, is a humanized IgG1 monoclonal antibody that has shown promising results in treating autoimmune diseases. Argenx was founded in 2008 and is headquartered in Gent, Belgium. For more information, visit www.argenx.com.